CEACAM5 and neoplasm: After completion of the trial, a significant improvement in several parameters, such as serum LF, glutathione-s-transferase (GST), IFN-γ, tumor marker carcinoembryonic antigen (CEA), blood cell count (WBC and RBC), renal and hepatic functions, were registered.